U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07013591) titled 'Nicotinamide Mmononucleotide in Patients Undergoing CABG Surgery' on May 09.
Brief Summary: The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.
Study Start Date: Oct. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Coronary Artery Bypass Graft
Intervention:
DRUG: MIB-626
An orally-administered stable crystalline tabl...